Andexxa reaches the end of the line in the US
AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Newsletters and Deep Dive digital magazine
AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
To stay relevant, medical affairs teams must adapt how they work to meet new demands with greater agility and efficiency.
Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.
Dermot Kenny, who leads STEM and Research Partnership at Inizio Advisory, shares his journey from bench scientist to CEO in a new 12 Questions With.
Editor's Picks
Newsletters and Deep Dive
digital magazine